Assessment rate of true dorsogluteal intramuscular drug injection using ultrasonography

Basit Öğe Kaydı
dc.contributor.authorÖzen, Özkan
dc.contributor.authorGünaydin, Mücahit
dc.contributor.authorTosun, Alptekin
dc.contributor.authorCoşkun, Zafer Ünsal
dc.contributor.authorAytekin, Kürşad
dc.contributor.authorTakır, Selçuk
dc.date.accessioned2021-02-19T21:16:19Z
dc.date.available2021-02-19T21:16:19Z
dc.date.issued2019
dc.departmentALKÜ
dc.descriptionTosun, Alptekin/0000-0003-1783-9171
dc.description.abstractObjective: Medications are generally administered by either the enteric or parenteral route. With parenteral administration, intramuscular (IM) is the preferred approach because it increases the bioavailability of the drug, acts more quickly than the enteric route. The aim of this study was to determine the rate of true dorsogluteal intramuscular drug injection and to determine the causes for application failures in practice by ultrasonography (US). Methods: The study was conducted from May 1 to May 30, 2017 in Giresun University Education and Research Hospital, Giresun, Turkey. We examined 60 patients who were administered dorsogluteal IM injection with a 38.1mm length needle. After the injection, localization of medications (whether intramuscular or subcutaneous adipose tissue [SAT]) was evaluated by Ultrasound. Results: Female/male ratio of the patients was 27/33, with a mean age of 39.78 +/- 2.16 years. Obese/ normal weight ratio was 20/40. The mean dorsogluteal area SAT thickness of obese and normal weight patients were 32.34 +/- 2.17 mm and 20.85 +/- 1.20 mm, respectively. In 23 of the patients, IM injected drug was observed in the SAT, while it was observed in the IM area in 37 patients. Medication was observed in IM area in 37 of 50 patients who dorsogluteal region SAT thickness was appropriate (SAT thickness lower than 33.1mm) for IM injection while it was seen in SAT area in 13 patients. Conclusions: SAT thickness values are important if IM drug injection is to be administered correctly. Unsuccessful IM injections may be seen even in patients with appropriate SAT thicknesses.
dc.identifier.doi10.12669/pjms.35.4.313
dc.identifier.endpage1137en_US
dc.identifier.issn1682-024X
dc.identifier.issue4en_US
dc.identifier.pmid31372156
dc.identifier.scopusqualityQ1
dc.identifier.startpage1132en_US
dc.identifier.urihttps://doi.org/10.12669/pjms.35.4.313
dc.identifier.urihttps://hdl.handle.net/20.500.12868/378
dc.identifier.volume35en_US
dc.identifier.wosWOS:000476976400047
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor0-belirlenecek
dc.language.isoen
dc.publisherProfessional Medical Publications
dc.relation.ispartofPakistan Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectIntramuscular drug injection
dc.subjectSubcutaneous adipose tissue
dc.subjectUltrasonography
dc.titleAssessment rate of true dorsogluteal intramuscular drug injection using ultrasonography
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu